作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
Abstract
Provided herein are novel compounds as NLRP3 inhibitors, pharmaceutical compositions, use of such compounds in treating cardiovascular diseases, and processes for preparing such compounds.
摘要
本文提供了作为NLRP3抑制剂的新型化合物、药物组合物、此类化合物在治疗心血管疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
2
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.新型三嗪类化合物作为治疗多种疾病的NLRP3抑制剂
ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12.
3
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.新型化合物作为用于治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂
ACS Med Chem Lett. 2025 Apr 26;16(5):760-761. doi: 10.1021/acsmedchemlett.5c00218. eCollection 2025 May 8.
4
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.作为用于治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2025 Apr 1;16(4):538-539. doi: 10.1021/acsmedchemlett.5c00143. eCollection 2025 Apr 10.
5
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.作为用于治疗阿尔茨海默病和帕金森病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 29;15(8):1203-1204. doi: 10.1021/acsmedchemlett.4c00343. eCollection 2024 Aug 8.
6
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.新型三嗪衍生物作为治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂
ACS Med Chem Lett. 2025 Jan 24;16(2):200-201. doi: 10.1021/acsmedchemlett.5c00020. eCollection 2025 Feb 13.
7
Pyridazine Compounds as NLRP3 Inhibitors for Treating Parkinson's Disease or Frontotemporal Dementia.哒嗪类化合物作为用于治疗帕金森病或额颞叶痴呆的NLRP3抑制剂
ACS Med Chem Lett. 2024 Nov 7;15(12):2083-2084. doi: 10.1021/acsmedchemlett.4c00523. eCollection 2024 Dec 12.
8
Novel Piperidine Substituted Pyrazolopyrimidine Derivatives as SGK1 Inhibitors for Treating Cardiovascular Diseases.新型哌啶取代的吡唑并嘧啶衍生物作为治疗心血管疾病的SGK1抑制剂
ACS Med Chem Lett. 2025 Apr 25;16(5):762-763. doi: 10.1021/acsmedchemlett.5c00217. eCollection 2025 May 8.
9
Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的单酰甘油脂肪酶抑制剂的新型杂环化合物。
ACS Med Chem Lett. 2024 Jun 21;15(7):994-995. doi: 10.1021/acsmedchemlett.4c00261. eCollection 2024 Jul 11.
10
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
本文引用的文献
1
Cardiovascular disease: Mitochondrial dynamics and mitophagy crosstalk mechanisms with novel programmed cell death and macrophage polarisation.心血管疾病：线粒体动力学与新型程序性细胞死亡和巨噬细胞极化的自噬串扰机制。
Pharmacol Res. 2024 Aug;206:107258. doi: 10.1016/j.phrs.2024.107258. Epub 2024 Jun 21.
2
Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement.靶向 SGLT2 抑制剂的炎症信号通路：对心血管健康和心脏细胞改善的深入了解。
Curr Probl Cardiol. 2024 May;49(5):102524. doi: 10.1016/j.cpcardiol.2024.102524. Epub 2024 Mar 16.
3
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases.NLRP3 炎性小体与细胞焦亡在心血管疾病中的作用。
Nat Rev Cardiol. 2024 Apr;21(4):219-237. doi: 10.1038/s41569-023-00946-3. Epub 2023 Nov 3.
4
Research progress of NLRP3 inflammasome and its inhibitors with aging diseases.NLRP3 炎性小体及其抑制剂与衰老相关性疾病的研究进展。
Eur J Pharmacol. 2023 Oct 15;957:175931. doi: 10.1016/j.ejphar.2023.175931. Epub 2023 Jul 24.
5
Beneficial effects of flavonoids on cardiovascular diseases by influencing NLRP3 inflammasome.黄酮类化合物通过影响 NLRP3 炎性小体对心血管疾病的有益作用。
Inflammopharmacology. 2023 Aug;31(4):1715-1729. doi: 10.1007/s10787-023-01249-2. Epub 2023 Jun 1.
Zotero 插件